Using genetically engineered human immortal melanocytes (hTERT/p53DD/CDK4(R24C))9,14,40 and melanoma xenograft mouse models, we examined the potential for APT2 inhibition by ML349 to impact melanocyte malignant transformation in vitro and ex vivo. The gene discussed is CDK4; the disease is melanoma.